Teplizumab, a CD3-directed monoclonal antibody that preserves -cell function in people with Stage 3 T1DM and delays the onset of Stage 3 T1DM in those with Stage 2 T1DM, represents the sole therapeutic agent to date that has received regulatory approval for the purpose of delaying the progression from Stage 2 to Stage 3 T1DM (129)
In addition, it also serves as a substrate for distinct metabolic pathways (such as the urea cycle) that profoundly affect immune cell biology, especially DCs, macrophages, and T cells
The study concluded that once-weekly doses of tirzepatide provided substantial and sustained reductions in body weight over the 72-week period
GLP-1 agonism: Delays gastric emptying, suppresses appetite centrally via hypothalamic signaling, and enhances glucose-dependent insulin secretion
Wellness Coaching Included Ongoing accountability to help you stay consistent